Levofloxacin failure in a patient with pneumococcal pneumonia

OBJECTIVE: To report a case of levofloxacin failure in a patient with a penicillin-sensitive Streptococcus pneumoniae pneumonia. CASE SUMMARY: A previously healthy, immunocompetent, 53-year-old white man presented with penicillin-sensitive S. pneumoniae pneumonia. The patient was empirically placed on levofloxacin monotherapy, which was continued due to a local penicillin shortage. When the patient failed to improve, further susceptibility testing was ordered. The organism was found to have a penicillin minimum inhibitory concentration (MIC) of 0.023 microgram/mL and a levofloxacin MIC of 6 micrograms/mL. Effective antimicrobial therapy was delayed, as clinicians did not anticipate fluoroquinolone resistance. DISCUSSION: Newer fluoroquinolones such as levofloxacin have good activity against most S. pneumoniae isolates and are used for the treatment of pneumonia. Although resistance to these agents is rare, it has been reported. Current guidelines from the National Committee for Clinical Laboratory Standards do not recommend initial fluoroquinolone susceptibility testing. CONCLUSIONS: As fluoroquinolone resistance may not be identified by susceptibility patterns to other antibiotics, early fluoroquinolone susceptibility testing and increased awareness of resistance may aid clinicians in their treatment of pneumococcal disease.

This article has been cited by other articles:

				L. Avrain, M. Garvey, N. Mesaros, Y. Glupczynski, M.-P. Mingeot-Leclercq, L. J. V. Piddock, P. M. Tulkens, R. Vanhoof, and F. Van Bambeke Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations J. Antimicrob. Chemother., November 1, 2007; 60(5): 965 - 972. [Abstract] [Full Text] [PDF]

				M. Woodhead, F. Blasi, S. Ewig, G. Huchon, M. Leven, A. Ortqvist, T. Schaberg, A. Torres, G. van der Heijden, and T. J. M. Verheij Guidelines for the management of adult lower respiratory tract infections Eur. Respir. J., December 1, 2005; 26(6): 1138 - 1180. [Abstract] [Full Text] [PDF]

				K. Kasahara, K. Maeda, K. Mikasa, K. Uno, K. Takahashi, M. Konishi, E. Yoshimoto, K. Murakawa, E. Kita, and H. Kimura Clonal Dissemination of Macrolide-Resistant and Penicillin-Susceptible Serotype 3 and Penicillin-Resistant Taiwan 19F-14 and 23F-15 Streptococcus pneumoniae Isolates in Japan: a Pilot Surveillance Study J. Clin. Microbiol., April 1, 2005; 43(4): 1640 - 1645. [Abstract] [Full Text] [PDF]

				V. Berry, J. Hoover, C. Singley, and G. Woodnutt Comparative Bacteriological Efficacy of Pharmacokinetically Enhanced Amoxicillin-Clavulanate against Streptococcus pneumoniae with Elevated Amoxicillin MICs and Haemophilus influenzae Antimicrob. Agents Chemother., March 1, 2005; 49(3): 908 - 915. [Abstract] [Full Text] [PDF]

				J. H. Jorgensen, S. A. Crawford, L. M. McElmeel, and C. G. Whitney Detection of Resistance to Gatifloxacin and Moxifloxacin in Streptococcus pneumoniae with the VITEK 2 Instrument J. Clin. Microbiol., December 1, 2004; 42(12): 5928 - 5930. [Abstract] [Full Text] [PDF]

				J. Powis, A. McGeer, K. Green, O. Vanderkooi, K. Weiss, G. Zhanel, T. Mazzulli, M. Kuhn, D. Church, R. Davidson, et al. In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002 Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3305 - 3311. [Abstract] [Full Text] [PDF]

				T. M. File Jr, J. Garau, F. Blasi, C. Chidiac, K. Klugman, H. Lode, J. R. Lonks, L. Mandell, J. Ramirez, and V. Yu Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia Chest, May 1, 2004; 125(5): 1888 - 1901. [Abstract] [Full Text] [PDF]

				N. R. Florea, P. R. Tessier, C. Zhang, C. H. Nightingale, and D. P. Nicolau Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations against Streptococcus pneumoniae Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1215 - 1221. [Abstract] [Full Text] [PDF]

				I. Morrissey and G. Tillotson Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae J. Antimicrob. Chemother., February 1, 2004; 53(2): 144 - 148. [Abstract] [Full Text] [PDF]

				S. M. Gunderson, R. A. Hayes, J. P. Quinn, and L. H. Danziger In Vitro Pharmacodynamic Activities of ABT-492, a Novel Quinolone, Compared to Those of Levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Antimicrob. Agents Chemother., January 1, 2004; 48(1): 203 - 208. [Abstract] [Full Text] [PDF]

				J. J Schentag, A. K Meagher, and A. Forrest Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials Ann. Pharmacother., October 1, 2003; 37(10): 1478 - 1488. [Abstract] [Full Text] [PDF]

				J. J Schentag, A. K Meagher, and A. Forrest Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models Ann. Pharmacother., September 1, 2003; 37(9): 1287 - 1298. [Abstract] [Full Text] [PDF]

				G. P. Allen, G. W. Kaatz, and M. J. Rybak Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model Antimicrob. Agents Chemother., August 1, 2003; 47(8): 2606 - 2614. [Abstract] [Full Text] [PDF]

				P.-R. Hsueh, L.-J. Teng, T.-L. Wu, D. Yang, W.-K. Huang, J.-M. Shyr, Y.-C. Chuang, J.-H. Wan, J.-J. Yan, J.-J. Lu, et al. Telithromycin- and Fluoroquinolone-Resistant Streptococcus pneumoniae in Taiwan with High Prevalence of Resistance to Macrolides and {beta}-Lactams: SMART Program 2001 Data Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2145 - 2151. [Abstract] [Full Text] [PDF]

				K. Weiss, G. S. Tillotson, and R. Guthrie Fluoroquinolones for Respiratory Infection : Too Valuable To Overuse (and Too Valuable To Misuse!) Chest, September 1, 2002; 122(3): 1102 - 1103. [Full Text] [PDF]

				K.P. Klugman Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections Eur. Respir. J., July 1, 2002; 20(36_suppl): 3S - 8s. [Abstract] [Full Text] [PDF]

				A. Ortqvist Treatment of community-acquired lower respiratory tract infections in adults Eur. Respir. J., July 1, 2002; 20(36_suppl): 40S - 53s. [Abstract] [Full Text] [PDF]